Use of risk scores to identify lower and higher risk subsets among COMPASS‐eligible patients with chronic coronary syndromes. Insights from the CLARIFY registry

BACKGROUND: The COMPASS trial showed a reduction of ischemic events with low‐dose rivaroxaban and aspirin in chronic coronary syndromes (CCS) compared with aspirin alone, at the expense of increased bleeding. HYPOTHESIS: The CHA(2)DS(2)VaSc Score, REACH Recurrent Ischemic (RIS), and REACH Bleeding R...

Descripción completa

Detalles Bibliográficos
Autores principales: Darmon, Arthur, Ducrocq, Gregory, Jasilek, Adam, Feldman, Laurent, Sorbets, Emmanuel, Ferrari, Roberto, Ford, Ian, Tardif, Jean‐Claude, Tendera, Michal, Fox, Kim M., Steg, Philippe Gabriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2020
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803362/
https://www.ncbi.nlm.nih.gov/pubmed/33274779
http://dx.doi.org/10.1002/clc.23505

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803362/
https://www.ncbi.nlm.nih.gov/pubmed/33274779
http://dx.doi.org/10.1002/clc.23505

Ejemplares similares